A randomized placebo-controlled trial of mebendazole for halitosis

Objective: To test whether mebendazole, an antiparasitic drug, would affect recovery from halitosis. Design: We conducted a randomized, double-blind, placebo-controlled trial between April 1999 and September 2001. Setting: A referral medical center. Patients: One hundred sixty-two children aged 5 to 16 years whose parents complained about their chronic bad breath. Interventions: Children were randomly assigned to receive mebendazole (n = 82) or placebo (n = 80). Main Outcome Measure: Parents whose children had halitosis were evaluated for halitosis at 2 months of treatment by questionnaire. The microbiologist investigated the stool samples of children for parasitosis at the beginning of the trial and also at the end of the trial in children who were treated with mebendazole. Results: Among those children who had evidence of parasites in stool samples at the beginning of the trial, 18 of 28 who were treated with mebendazole recovered from halitosis, compared with 2 of 24 who received placebo (relative risk [RR] for recovery, 7.7; 95% confidence interval [CI], 2.0-29.9). Among those who did not have stool parasites, 14 of 52 improved with mebendazole, compared with 10 of 48 taking placebo (RR, 1.3; 95% CI, 0.6-2.6). Mebendazole intake made a significant difference whether or not the children had parasites (P=.002). Conclusions: Parasitosis should be considered as a possible cause of halitosis in the pediatric patient population. Mebendazole therapy seems to offer benefit to those children with parasites as a potential cause of their halitosis.

Yazar Ermis B.
Aslan T.
Beder L.
Unalacak M.
Yayın Türü Article
Tek Biçim Adres https://hdl.handle.net/20.500.12628/4023
Tek Biçim Adres 10.1001/archpedi.156.10.995
Koleksiyonlar Araştırma Çıktıları | WoS | Scopus | TR-Dizin | PubMed | SOBİAD
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu
Dergi Adı Archives of Pediatrics and Adolescent Medicine
Dergi Cilt Bilgisi 156
Dergi Sayısı 10
Sayfalar 995 - 998
Yayın Yılı 2002
Eser Adı
[dc.title]
A randomized placebo-controlled trial of mebendazole for halitosis
Yazar
[dc.contributor.author]
Ermis B.
Yazar
[dc.contributor.author]
Aslan T.
Yazar
[dc.contributor.author]
Beder L.
Yazar
[dc.contributor.author]
Unalacak M.
Yayın Yılı
[dc.date.issued]
2002
Yayıncı
[dc.publisher]
American Medical Association
Yayın Türü
[dc.type]
article
Özet
[dc.description.abstract]
Objective: To test whether mebendazole, an antiparasitic drug, would affect recovery from halitosis. Design: We conducted a randomized, double-blind, placebo-controlled trial between April 1999 and September 2001. Setting: A referral medical center. Patients: One hundred sixty-two children aged 5 to 16 years whose parents complained about their chronic bad breath. Interventions: Children were randomly assigned to receive mebendazole (n = 82) or placebo (n = 80). Main Outcome Measure: Parents whose children had halitosis were evaluated for halitosis at 2 months of treatment by questionnaire. The microbiologist investigated the stool samples of children for parasitosis at the beginning of the trial and also at the end of the trial in children who were treated with mebendazole. Results: Among those children who had evidence of parasites in stool samples at the beginning of the trial, 18 of 28 who were treated with mebendazole recovered from halitosis, compared with 2 of 24 who received placebo (relative risk [RR] for recovery, 7.7; 95% confidence interval [CI], 2.0-29.9). Among those who did not have stool parasites, 14 of 52 improved with mebendazole, compared with 10 of 48 taking placebo (RR, 1.3; 95% CI, 0.6-2.6). Mebendazole intake made a significant difference whether or not the children had parasites (P=.002). Conclusions: Parasitosis should be considered as a possible cause of halitosis in the pediatric patient population. Mebendazole therapy seems to offer benefit to those children with parasites as a potential cause of their halitosis.
Kayıt Giriş Tarihi
[dc.date.accessioned]
2019-12-23
Açık Erişim Tarihi
[dc.date.available]
2019-12-23
Yayın Dili
[dc.language.iso]
eng
Haklar
[dc.rights]
info:eu-repo/semantics/openAccess
ISSN
[dc.identifier.issn]
1072-4710
İlk Sayfa Sayısı
[dc.identifier.startpage]
995
Son Sayfa Sayısı
[dc.identifier.endpage]
998
Dergi Adı
[dc.relation.journal]
Archives of Pediatrics and Adolescent Medicine
Dergi Sayısı
[dc.identifier.issue]
10
Dergi Cilt Bilgisi
[dc.identifier.volume]
156
Tek Biçim Adres
[dc.identifier.uri]
https://dx.doi.org/10.1001/archpedi.156.10.995
Tek Biçim Adres
[dc.identifier.uri]
https://hdl.handle.net/20.500.12628/4023
Görüntülenme Sayısı ( Şehir )
Görüntülenme Sayısı ( Ülke )
Görüntülenme Sayısı ( Zaman Dağılımı )
Görüntülenme
9
09.12.2022 tarihinden bu yana
İndirme
1
09.12.2022 tarihinden bu yana
Son Erişim Tarihi
09 Şubat 2024 07:23
Google Kontrol
Tıklayınız
children halitosis mebendazole parasites placebo treated whether samples beginning Mebendazole recovery compared interval evidence recovered (relative confidence received Objective pediatric Conclusions Parasitosis should considered possible patient population therapy benefit potential difference improved taking significant intake
6698 sayılı Kişisel Verilerin Korunması Kanunu kapsamında yükümlülüklerimiz ve çerez politikamız hakkında bilgi sahibi olmak için alttaki bağlantıyı kullanabilirsiniz.

creativecommons
Bu site altında yer alan tüm kaynaklar Creative Commons Alıntı-GayriTicari-Türetilemez 4.0 Uluslararası Lisansı ile lisanslanmıştır.
Platforms